Komori
Occurring Fact4506Sumitomo Pharma Co.,Ltd.Pharmaceuticals

Regarding a Report on Our Company (Additional Explanation Concerning “Sumitomo Chemical and Sumitomo Pharmaceutical: The ¥116 Billion Swiss Shuffle”)”

Sumitomo Pharma provided additional explanations, including its rebuttal and supporting rationale, regarding the comments on financial performance and accounting treatment contained in the report by Gotham City Research. The disclosure does not correct financial results or earnings forecasts.

Worth reading
34Immaterial
Scored from 1 of 3 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure
The number of days elapsed cannot be calculated because the original disclosure date is unknown.
This correction2026-08-07
Impact on Business Performance (the company’s explanation)

The transactions in question are intragroup transactions and are eliminated in the consolidated financial statements. Accordingly, they have no impact on the consolidated financial statements.

Reason for correction

To provide additional explanations of the Company’s views and supporting rationale regarding the report’s main claims, following the report published by Gotham City Research LLC on 3 August 2026.

What was corrected and how
ItemDetails
Reason for correctionTo provide additional explanations of the Company’s views and supporting rationale regarding the report’s main claims, following the report published by Gotham City Research LLC on 3 August 2026.
Impact on Business PerformanceThe transactions in question are intragroup transactions and are eliminated in the consolidated financial statements. Accordingly, they have no impact on the consolidated financial statements.
Items this document does not state (4)
Disclosure subject to correctionOriginal disclosure dateLocation of correctionDetails of correction

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To provide additional explanations of the Company’s views and supporting rationale regarding the report’s main claims, in light of the serious impact that the report by Gotham City Research dated 3 August 2026 may have on investors’ decision-making.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Regarding a Report on Our Company (Additional Explanation Concerning “Sumitomo Chemical and Sumitomo Pharmaceutical: The ¥116 Billion Swiss Shuffle”)” | Sumitomo Pharma Co.,Ltd. (4506) timely disclosure | Komori